Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3203

Effects of Multiple-target Anti-microRNA Antisense Oligodeoxyribonucleotides on Proliferation and Migration of Gastric Cancer Cells  

Xu, Ling (Department of Gastroenterology, Tenth People's Hospital of Tongji University)
Dai, Wei-Qi (Department of Gastroenterology, Tenth People's Hospital of Tongji University)
Xu, Xuan-Fu (Department of Gastroenterology, Tenth People's Hospital of Tongji University)
Wang, Fan (Department of Gastroenterology, Tenth People's Hospital of Tongji University)
He, Lei (Department of Gastroenterology, Tenth People's Hospital of Tongji University)
Guo, Chuan-Yong (Department of Gastroenterology, Tenth People's Hospital of Tongji University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3203-3207 More about this Journal
Abstract
Backgrounds: To investigate the inhibiting effects of multi-target anti-microRNA antisense oligonucleotide (MTg-AMOs) on proliferation and migration of human gastric cancer cells. Methods: Single anti-microRNA antisense oligonucleotides (AMOs) and MTg-AMOs for miR-221, 21, and 106a were designed and transfected into SGC7901, a gastric cancer cell line, to target the activity of these miRNAs. Their expression was analyzed using stem-loop RT-PCR and effects of MTg-AMOs on human gastric cancer cells were determined using the following two assay methods: CCK8 for cell proliferation and transwells for migration. Results: In the CCK-8 cell proliferation assay, $0.6{\mu}mol/L$ was selected as the preferred concentration of MTg-AMOs and incubation time was 72 hours. Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs (P = 0.014, 0.024; 0.038, respectively). Migration activity was also clearly decreased as compared to those in randomized and blank control groups ($28{\pm}4$ Vs $54{\pm}3$, P <0.01; $28{\pm}4$ Vs $59{\pm}4$, P < 0.01). Conclusions: MTg-AMOs can specifically inhibit the expression of multiple miRNAs, and effectively antagonize proliferation and migration of gastric cancer cells promoted by oncomirs.
Keywords
MicroRNAs; stomach neoplasms; oligonucleotides; antisense; cell proliferation; migration;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bartels CL and Tsongalis GJ (2009). MicroRNAs: novel biomarkers for human cancer. Clin Chem, 55, 623-31.   DOI
2 Chen CF, Ridzon DA and Broomer AJ, et al (2005). Real- time quantification of microRNAs by stem-loop RT- PCR. Nucleic Acids Res, 33, e179.   DOI
3 Chen Y, Stallings RL (2007). Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res, 67, 976-83.   DOI
4 Denli AM, Tops BJ, Plasterk PH, et al (2004). Processing of primary microRNAs by the microprocessor complex. Nature, 432, 231-5.   DOI
5 Esquela-Kerscher A and Slack FJ (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69.   DOI
6 Ferdin J, Kunej T and Calin GA (2010). Non-coding RNAs: Identification of Cancer-Associated microRNAs by Gene Profiling. Technol Cancer Res Treat, 9, 123-38.   DOI
7 Gregory RI, Yan K, Amuthan G, et al (2004). The microprocessor complex mediates the genesis of microRNAs. Nature, 432, 235-40.   DOI
8 Krutzfeldt J, Rajewsky N, Braich R, et al (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature, 438, 685-9.   DOI
9 Lee EJ, Gusev Y, Jiang J, et al (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer, 120, 1046-54.
10 Liu W, Mao SY and Zhu WY (2007). Impact of tiny miRNAs on cancers. World J Gastroenterol, 13, 497-502.   DOI
11 Orom UA, Kauppinen S, Lund AH (2006). LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene, 372, 137-41.   DOI
12 Schetter AJ, Leung SY, Sohn JJ, et al (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-36.   DOI
13 Wang V and Wu W (2009). MicroRNA-based therapeutics for cancer. BioDrugs, 23, 15-23.   DOI
14 Li C, Feng Y, Coukos G, et al (2009). Therapeutic microRNA strategies in human cancer. AAPS J, 11, 747-57.   DOI
15 Lu Y, Xiao J, Lin H, et al (2009). A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res, 37, e24.   DOI
16 Wagner RW (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature, 372, 333-5.   DOI
17 Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98.   DOI   ScienceOn
18 Weiler J, Hunziker J, Hall J (2006). Anti-miRNA-oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease. Gene Ther, 13, 496-502.   DOI   ScienceOn
19 Xiao B, Guo J, Miao Y, et al (2009). Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta, 400, 97-102.   DOI